Which has stronger earnings and valuation, IXI or REDX?

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IXICO £7.28M 2.23 -£3.58M -£1.95 N/A Redx Pharma £4.20M 0.00 -£33.16M -£0.10 N/A

Is IXI or REDX more profitable?

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets IXICO -24.98% -16.18% -10.40% Redx Pharma N/A -180.80% -43.95%

Which has preferable earnings and valuation, ETX or IXI?

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio e-therapeutics £295K 0.00 -£10.06M -£0.02 N/A IXICO £7.28M 2.23 -£3.58M -£1.95 N/A

Is ETX or IXI more profitable?

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets e-therapeutics N/A -38.75% -29.10% IXICO -24.98% -16.18% -10.40%

Do analysts prefer HVO or IXI?

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 129.04%. Given hVIVO's stronger consensus rating and higher probable upside, equities analysts plainly believe hVIVO is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, HVO or IXI?

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £38.85M 1.16 £17.84M -£0.87 N/A IXICO £7.28M 2.23 -£3.58M -£1.95 N/A

Is HVO or IXI more profitable?

IXICO has a net margin of -24.98% compared to hVIVO's net margin of -31.76%. IXICO's return on equity of -16.18% beat hVIVO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -31.76% -35.13% 11.97% IXICO -24.98% -16.18% -10.40%

Does the media prefer HVO or IXI?

In the previous week, hVIVO had 2 more articles in the media than IXICO. MarketBeat recorded 3 mentions for hVIVO and 1 mentions for IXICO. IXICO's average media sentiment score of 0.75 beat hVIVO's score of 0.14 indicating that IXICO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment hVIVO 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IXICO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to COIL or IXI?

In the previous week, Roquefort Therapeutics had 2 more articles in the media than IXICO. MarketBeat recorded 3 mentions for Roquefort Therapeutics and 1 mentions for IXICO. IXICO's average media sentiment score of 0.75 beat Roquefort Therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roquefort Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IXICO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, C4XD or IXI?

C4X Discovery has higher revenue and earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio C4X Discovery £24.68M 0.00 £10.57M £0.04 N/A IXICO £7.28M 2.23 -£3.58M -£1.95 N/A

Is C4XD or IXI more profitable?

C4X Discovery has a net margin of 42.81% compared to IXICO's net margin of -24.98%. C4X Discovery's return on equity of 55.38% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets C4X Discovery 42.81% 55.38% 28.04% IXICO -24.98% -16.18% -10.40%

IXICO (IXI) Competitors

GBX 7.40 0.00 (-0.01%)

As of 04:56 AM Eastern

Compare

IXI vs. REDX, ETX, HVO, COIL, and C4XD

Should you buy IXICO stock or one of its competitors? IXICO's main competitors and comparable companies include Redx Pharma (REDX), e-therapeutics (ETX), hVIVO (HVO), Roquefort Therapeutics (COIL), and C4X Discovery (C4XD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IXICO compare to Redx Pharma?

IXICO (LON:IXI) and Redx Pharma (LON:REDX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Redx Pharma	N/A	-180.80%	-43.95%

In the previous week, IXICO had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Redx Pharma. IXICO's average media sentiment score of 0.75 beat Redx Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
Redx Pharma	Neutral

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.23	-£3.58M	-£1.95	N/A
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A

30.6% of IXICO shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 3.1% of IXICO shares are owned by company insiders. Comparatively, 18.4% of Redx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

IXICO has a beta of 0.106, meaning that its stock price is 89% less volatile than the broader market. Comparatively, Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market.

Summary

IXICO beats Redx Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to e-therapeutics?

e-therapeutics (LON:ETX) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

e-therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, IXICO has a beta of 0.106, suggesting that its share price is 89% less volatile than the broader market.

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
e-therapeutics	N/A	-38.75%	-29.10%
IXICO	-24.98%	-16.18%	-10.40%

In the previous week, IXICO had 1 more articles in the media than e-therapeutics. MarketBeat recorded 1 mentions for IXICO and 0 mentions for e-therapeutics. IXICO's average media sentiment score of 0.75 beat e-therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
e-therapeutics	Neutral
IXICO	Positive

26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 30.6% of IXICO shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by company insiders. Comparatively, 3.1% of IXICO shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A
IXICO	£7.28M	2.23	-£3.58M	-£1.95	N/A

Summary

IXICO beats e-therapeutics on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to hVIVO?

hVIVO (LON:HVO) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk.

hVIVO presently has a consensus price target of GBX 15, suggesting a potential upside of 129.04%. Given hVIVO's stronger consensus rating and higher probable upside, equities analysts plainly believe hVIVO is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.7% of hVIVO shares are held by institutional investors. Comparatively, 30.6% of IXICO shares are held by institutional investors. 4.9% of hVIVO shares are held by insiders. Comparatively, 3.1% of IXICO shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£38.85M	1.16	£17.84M	-£0.87	N/A
IXICO	£7.28M	2.23	-£3.58M	-£1.95	N/A

IXICO has a net margin of -24.98% compared to hVIVO's net margin of -31.76%. IXICO's return on equity of -16.18% beat hVIVO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-31.76%	-35.13%	11.97%
IXICO	-24.98%	-16.18%	-10.40%

In the previous week, hVIVO had 2 more articles in the media than IXICO. MarketBeat recorded 3 mentions for hVIVO and 1 mentions for IXICO. IXICO's average media sentiment score of 0.75 beat hVIVO's score of 0.14 indicating that IXICO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
hVIVO	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IXICO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

hVIVO has a beta of 1.694, meaning that its stock price is 69% more volatile than the broader market. Comparatively, IXICO has a beta of 0.106, meaning that its stock price is 89% less volatile than the broader market.

Summary

hVIVO beats IXICO on 10 of the 16 factors compared between the two stocks.

How does IXICO compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market. Comparatively, IXICO has a beta of 0.106, meaning that its stock price is 89% less volatile than the broader market.

IXICO has a net margin of -24.98% compared to Roquefort Therapeutics' net margin of -57,057.07%. IXICO's return on equity of -16.18% beat Roquefort Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%
IXICO	-24.98%	-16.18%	-10.40%

In the previous week, Roquefort Therapeutics had 2 more articles in the media than IXICO. MarketBeat recorded 3 mentions for Roquefort Therapeutics and 1 mentions for IXICO. IXICO's average media sentiment score of 0.75 beat Roquefort Therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roquefort Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IXICO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.8% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 30.6% of IXICO shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Comparatively, 3.1% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Roquefort Therapeutics has higher earnings, but lower revenue than IXICO. IXICO is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A
IXICO	£7.28M	2.23	-£3.58M	-£1.95	N/A

Summary

IXICO beats Roquefort Therapeutics on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to C4X Discovery?

C4X Discovery (LON:C4XD) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, IXICO had 1 more articles in the media than C4X Discovery. MarketBeat recorded 1 mentions for IXICO and 0 mentions for C4X Discovery. IXICO's average media sentiment score of 0.75 beat C4X Discovery's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
C4X Discovery	Neutral
IXICO	Positive

C4X Discovery has a net margin of 42.81% compared to IXICO's net margin of -24.98%. C4X Discovery's return on equity of 55.38% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4X Discovery	42.81%	55.38%	28.04%
IXICO	-24.98%	-16.18%	-10.40%

52.1% of C4X Discovery shares are owned by institutional investors. Comparatively, 30.6% of IXICO shares are owned by institutional investors. 27.1% of C4X Discovery shares are owned by insiders. Comparatively, 3.1% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

C4X Discovery has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, IXICO has a beta of 0.106, meaning that its stock price is 89% less volatile than the broader market.

C4X Discovery has higher revenue and earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4X Discovery	£24.68M	0.00	£10.57M	£0.04	N/A
IXICO	£7.28M	2.23	-£3.58M	-£1.95	N/A

Summary

C4X Discovery beats IXICO on 10 of the 12 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£16.20M	£3.98B	£7.32B	£2.89B
Dividend Yield	1.27%	3.63%	2.52%	6.22%
P/E Ratio	-3.79	13.88	274.06	366.55
Price / Sales	2.23	1,343.72	637.81	90,071.63
Price / Cash	2.25	113.29	77.80	27.89
Price / Book	0.38	15.21	10.40	6.35
Net Income	-£3.58M	-£22.82M	£3.49B	£5.89B
7 Day Performance	5.70%	-1.72%	-0.69%	0.24%
1 Month Performance	-7.16%	-6.17%	-3.18%	6.42%
1 Year Performance	-39.85%	30.66%	15.13%	19.37%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 7.40 0.0%	N/A	-35.7%	£16.20M	£7.28M	N/A	79	Gap Up
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume
HVO hVIVO	1.6556 of 5 stars	GBX 6.10 -4.7%	GBX 15 +145.9%	-25.5%	£41.99M	£46.77M	N/A	N/A	News Coverage
COIL Roquefort Therapeutics	N/A	GBX 8.50 +8.3%	N/A	-52.9%	£36.28M	N/A	N/A	9	Analyst Forecast Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors